Search PubMed⌕ Search

Biomedical subjects

Y Aso

Publications and source records attributed to Y Aso.

At least 307 records · Page 17Linked to original sources
PubMed1987

[Antiemetic effects of MS-5080 associated with cisplatin chemotherapy--an attempt in assessment based on the sample score system using multivariate analysis].

Effect of a new antiemetic drug, MS-5080 was evaluated against nausea and vomiting induced by chemotherapy including cisplatin. Fifty patients with various urological malignancies were registered into this study, which were distributed to the aliquot number with a respective dose schedule of 2, 3, 4 and 5 mg/kg body weight of MS-5080. Forty-seven patients with a total of 73 chemotherapeutic courses were eligible for evaluation of antiemetic efficacy, whereas the side effect of MS-5080 were evaluated in 48 patients with a total of 74 courses. Antiemetic efficacy was evaluated in terms of duration of nausea, duration of vomiting, duration of food intolerance, and the number of vomiting episodes. No statistically significant difference was observed in relation to the dose dependency of MS-5080. In assessment of the side effects, a relatively high incidence of diarrhea was observed compared to the other known antiemetic drugs. In the present study, we attempted an evaluation based on the sample score system using multivariate analysis. The results were correlated well with results of a grading system of efficacy that were determined by each physician who treated the patients.

Adult↗
PubMed1986

Intraoperative blood pressure control by ATP in pheochromocytoma.

Three cases of pheochromocytoma which were successfully treated with the use of adenosine triphosphate (ATP) during the operation are reported. The mechanism of the hypotensive effect of ATP has been proved due to the antagonizing action of the agent to the vasoconstriction by noradrenaline and/or sympathetic nerve stimulation. In these 3 cases, ATP has been safely and effectively applied to control blood pressure in pheochromocytoma. ATP could be used as the first-choice drug to keep the circulatory state stable during surgery for pheochromocytoma.

Adenosine Triphosphate↗
PubMed1986

[Clinical effect of allylestrenol on benign prostatic hypertrophy].

Allylestrenol at the daily dose of 50 mg was administered to 45 patients with benign prostatic hypertrophy. The treatment was performed for more than 12 weeks in 40 patients, and improvements, marked and moderate, were observed in 22 patients (55%) in the overall judgement. As side effects of this drug, decrease of potency was observed in 3 cases, decrease of libido in 1 case, pigmentation on breasts in 2 cases, palpitation in 2 cases, short breath in 1 case, and gastrointestinal symptoms in 1 case. However, these side effects were not serious. Our trial suggests that the treatment of benign prostatic hypertrophy with allylestrenol can be useful in urological clinics.

Aged↗
PubMed1986

[Treatment of prostatic carcinoma with daily subcutaneous injection of the LH-RH analogue, ICI 118630].

Between April, 1984 and March, 1985 in 14 centers, 33 patients with prostatic cancer of our 14 centers were randomized to subcutaneously receive either 125, 250, or 500 micrograms/day of ICI 118,630, an LH-RH analogue, for 12 weeks, and the clinical efficacy, safety and endocrinal effects of the drug by dose were examined. An objective partial response was obtained in 44.4% of the 125 micrograms-treated group, in 50.0% of the 250 micrograms-treated group, and 42.9% of the 500 micrograms-treated group, showing no significant difference between the groups. General subjective response rates in these three groups were respectively 75.0%, 62.5%, and 85.7%, not differing from each other significantly. No significant difference was observed in endocrinal effect which was seen in 58.3%, 66.7%, and 100% of 125 micrograms, 250 micrograms, and 500 micrograms groups, respectively. Medical castration was attained in 4.1 +/- 2.0 weeks on average. Adverse reactions observed included fever up to 37 degrees C in 1 of the 13 (7.3%) patients treated with 125 micrograms, and hot feeling at the injection site and flare in 1 of the 8 (12.5%) patients treated with 500 micrograms, which were all mild. These patients responded to further ICI 118,630 therapy without requiring any treatment for the adverse reactions.

Adenocarcinoma↗
PubMed1986

[Randomized cross-over study on the effects of methylprednisolone, metoclopramide and droperidol on the control of nausea and vomiting associated with cis-platinum chemotherapy].

A randomized cross-over study on the effects of methylprednisolone (MP), metoclopramide (MT) and droperidol (DP) on the control of nausea and vomiting associated with cis-platinum chemotherapy was performed. Sixty-three patients were entered into the study; 60 patients (21 treated with MP, 18 with MT and 21 with DP) were eligible for evaluation of antiemetic efficacy, whereas the side effects of these drugs were evaluated in all of the 63 patients. Out of the above 60 patients, 36 were entered into the cross-over treatment. Antiemetic efficacy was evaluated in terms of duration of nausea, duration of vomiting, frequency of vomiting, duration of inability to take food and the amount of food first taken after cis-platinum treatment. Generally, the MP-treated group of patients showed favorable effects in these points, MP being especially more effective than other drugs with a statistically significant difference for the control of nausea and disturbed intake of food during the first 24 hours after the treatment with CDDP. Anticipatory nausea and vomiting were not observed in this study. Side-effects were minimal and all of the patients except one, who showed severe diarrhea following administration of MT and could not tolerate the treatment thereafter, were safely treated.

Adult↗
PubMed1986

[Intravesical chemotherapy of (2''R)-4'-O-tetrahydropyranyladriamycin in bladder tumor].

The effect of (2"R)-4'-0-tetrahydropyranyladriamycin (THP), a derivative of adriamycin (ADM) on bladder tumors was evaluated by intravesical instillation. Twenty-one patients with bladder tumors were treated with THP instillation into the bladder. THP (20-30 mg dissolved in 20-40 ml of distilled water) was instilled into the bladder daily for 3 consecutive days as a course. The patients received 2 to 5 courses in total. Of 21 patients, 4 showed complete disappearance of the bladder tumors, while partial response (50% tumor reduction) was observed in 6 cases. Therefore, the overall response rate was 48%. However, with regard to the 16 patients with superficial bladder tumors (Ta, T1) an overall response rate of 63% was noted. The main side effect of THP instillation was temporary bladder irritability, which was seen in 57% of all the patients. No cases revealed systemic side effects. The same antitumor effect was obtained at a lower concentration of THP in the intravesical chemotherapy, compared with that of ADM. It was concluded that THP is a useful drug for the intravesical chemotherapy of bladder tumors.

Aged↗
PubMed1986

[Phase II collaborative study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) for urological malignancies--Urological Co-operative THP Study Group].

A Phase II clinical trial of a new anthracycline, (2''R)-4'-0-tetrahydropyranyladriamycin (THP), was performed in 137 patients with urological malignancies. Out of them, 111 patients were evaluated for tumor responses and 125 patients were evaluated for adverse effects. In cases of intravenous administration, overall response rate was 18.5% (22.2% for bladder cancer, 30.0% for tumors of the renal pelvis and ureter, and 6.7% for prostatic cancer). In the case of intra-arterial administration, overall response rate was 42.9% (50.0% for bladder cancer). For 50 patients with superficial bladder cancer intravesical chemotherapy with THP was performed. Sixteen patients showed complete disappearance of the tumor, 2 patients showed more than 90% tumor regression and 12 patients showed more than 50% tumor regression, respectively. Overall response rate was 60%. Cardiotoxicity was minimal. Alopecia was noted in a total of 16 patients, but this was minimal. Leukocytopenia was the major adverse effect among patients undergoing systemic THP administration. In conclusion, THP was most effective against transitional cell carcinoma of the urinary tract.

Adult↗